Gut microbiota modulating therapy for diabetes mellitus should be individualized.

IF 4.2 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

World Journal of Diabetes Pub Date : 2024-10-15 DOI:10.4239/wjd.v15.i10.2152

Jin Wang, Hong-Juan Wei, Rui-Feng Mao, Xin Chang

引用次数: 0

Abstract

In this editorial, we commented on two articles published online in August and September 2024 in the World Journal of Diabetes, which focused on modifying the gut microbiota (GM) to prevent or delay the progression of diabetes mellitus (DM) and DM-related complications. Numerous studies, many of which are animal studies, have indicated the potential role of GM in the pathogenesis of DM. However, the detailed causality and mechanisms between GM and DM have not been fully clarified. Although there have been some reports of a potential role of modifying the GM in treating DM, most lack long-term observations and are not mechanistic. Additionally, the GM and its role in DM might vary among individuals; therefore, GM-targeted interventions should be individualized to realize their therapeutic potential.

查看原文本刊更多论文

针对糖尿病的肠道微生物群调节疗法应因人而异。

在这篇社论中，我们对 2024 年 8 月和 9 月在线发表在《世界糖尿病杂志》（World Journal of Diabetes）上的两篇文章进行了评论，这两篇文章的重点是改变肠道微生物群（GM）以预防或延缓糖尿病（DM）和 DM 相关并发症的进展。大量研究（其中许多是动物研究）表明，肠道微生物群在糖尿病的发病机制中具有潜在作用。然而，转基因与糖尿病之间的详细因果关系和机制尚未完全明确。虽然有一些报告指出改变基因改造在治疗 DM 中的潜在作用，但大多数报告缺乏长期观察，也没有从机理角度进行分析。此外，全球机制及其在 DM 中的作用可能因人而异；因此，以全球机制为目标的干预措施应因人而异，以实现其治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Diabetes ENDOCRINOLOGY & METABOLISM-

自引率

2.40%

发文量

909

期刊介绍： The WJD is a high-quality, peer reviewed, open-access journal. The primary task of WJD is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of diabetes. In order to promote productive academic communication, the peer review process for the WJD is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJD are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in diabetes. Scope: Diabetes Complications, Experimental Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes, Gestational, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Coma, Diabetic Ketoacidosis, Diabetic Nephropathies, Diabetic Neuropathies, Donohue Syndrome, Fetal Macrosomia, and Prediabetic State.